Aquilo Capital Management is an investment fund managing more than $133 billion ran by Tony Berta. There are currently 10 companies in Mr. Berta’s portfolio. The largest investments include Arrowhead Pharmaceuticals In and Regenxbio Inc, together worth $45.1 billion.
As of 8th May 2024, Aquilo Capital Management’s top holding is 908,474 shares of Arrowhead Pharmaceuticals In currently worth over $26 billion and making up 19.5% of the portfolio value.
In addition, the fund holds 906,248 shares of Regenxbio Inc worth $19.1 billion, whose value fell 17.5% in the past six months.
The third-largest holding is Blueprint Medicines Corp worth $17.3 billion and the next is Arvinas Inc worth $16.8 billion, with 405,766 shares owned.
Currently, Aquilo Capital Management's portfolio is worth at least $133 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Aquilo Capital Management office and employees reside in San Francisco, California. According to the last 13-F report filed with the SEC, Tony Berta serves as the Chief Compliance Officer at Aquilo Capital Management.
In the most recent 13F filing, Aquilo Capital Management revealed that it had opened a new position in
Precision BioSciences and bought 385,440 shares worth $5.23 billion.
This means they effectively own approximately 0.1% of the company.
Precision BioSciences makes up
4.9%
of the fund's Health Care sector allocation and has grown its share price by 1413.2% in the past year.
The investment fund also strengthened its position in Regenxbio Inc by buying
103,824 additional shares.
This makes their stake in Regenxbio Inc total 906,248 shares worth $19.1 billion.
Regenxbio Inc dropped 27.2% in the past year.
On the other hand, Tony Berta disclosed a decreased stake in Blueprint Medicines Corp by 0.3%.
This leaves the value of the investment at $17.3 billion and 182,151 shares.
The two most similar investment funds to Aquilo Capital Management are Dunhill and Successful Portfolios. They manage $133 billion and $134 billion respectively.
Aquilo Capital Management’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 80.5% of
the total portfolio value.
The fund focuses on investments in the United States as
60.0% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
approximately 0.1% of the total holdings value.
On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $1.02 billion.
These positions were updated on May 15th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Arrowhead Pharmaceuticals In |
No change
908,474
|
$25,982,356,000 | 19.47% |
| Regenxbio Inc |
12.94%
906,248
|
$19,094,645,000 | 14.31% |
| Blueprint Medicines Corp |
28.52%
182,151
|
$17,278,844,000 | 12.95% |
| Arvinas Inc |
17.05%
405,766
|
$16,750,020,000 | 12.55% |
| Kymera Therapeutics, Inc. |
55.89%
388,743
|
$15,627,469,000 | 11.71% |
| Silence Therapeutics plc |
44.96%
574,214
|
$12,403,022,000 | 9.30% |
| Merus N.V |
28.16%
255,109
|
$11,487,558,000 | 8.61% |
| Sutro Biopharma Inc |
177.06%
1,165,466
|
$6,584,883,000 | 4.94% |
| Precision BioSciences, Inc. |
Opened
385,440
|
$5,226,566,000 | 3.92% |
| Repare Therapeutics Inc. |
No change
633,271
|
$2,982,706,000 | 2.24% |
| No transactions found | |||
| Showing first 500 out of 10 holdings | |||